- Trials with a EudraCT protocol (370)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
370 result(s) found for: Hemoglobin H.
Displaying page 1 of 19.
EudraCT Number: 2021-004928-15 | Sponsor Protocol Number: CA056-015 | Start Date*: 2022-09-28 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: A Phase 2, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of Luspatercept (BMS-986346/ACE-536) for the Treatment of Anemia in Adults with Alpha... | |||||||||||||
Medical condition: Alpha (α)-thalassemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Trial now transitioned) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005267-48 | Sponsor Protocol Number: 4202-HEM-201 | Start Date*: 2022-10-17 | ||||||||||||||||
Sponsor Name:FORMA THERAPEUTICS, INC. | ||||||||||||||||||
Full Title: A Phase 2 Open-Label Study to Evaluate Safety and Clinical Activity of FT-4202 in Patients with Thalassemia or Sickle Cell Disease | ||||||||||||||||||
Medical condition: Sickle cell disease (SCD) or thalassemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004568-37 | Sponsor Protocol Number: INV543 | Start Date*: 2018-11-30 | ||||||||||||||||
Sponsor Name:Nova Laboratories Limited | ||||||||||||||||||
Full Title: A prospective open label, pharmacokinetic study of an oral hydroxyurea solution in children with sickle cell anemia | ||||||||||||||||||
Medical condition: Sickle Cell Anaemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001631-46 | Sponsor Protocol Number: NL65876.078.18 | Start Date*: 2019-02-14 | |||||||||||
Sponsor Name:Erasmus University Medical Center | |||||||||||||
Full Title: Implementation of pharmacokinetic-guided dosing of DDAVP and VWF-containing concentrates in von Willebrand disease | |||||||||||||
Medical condition: Von Willebrand disease | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003459-39 | Sponsor Protocol Number: AG348-C-011 | Start Date*: 2019-04-10 | |||||||||||
Sponsor Name:Agios Pharmaceuticals, Inc. | |||||||||||||
Full Title: An Open-Label, Multicenter, Extension Study of AG-348 in Adult Subjects with Pyruvate Kinase Deficiency Previously Enrolled in AG-348 Studies | |||||||||||||
Medical condition: Pyruvate Kinase Deficiency Haemolytic anaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) FR (Ongoing) IE (Ongoing) NL (Ongoing) DE (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001006-18 | Sponsor Protocol Number: D5136C00007 | Start Date*: 2014-08-27 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: Multicenter, open-label, randomised, pharmacokinetic (PK) and pharmacodynamic (PD) dose-ranging Phase II study of ticagrelor followed by a double-blind, randomised, parallel-group, placebo-controll... | |||||||||||||
Medical condition: Investigation of platelet aggregation in paediatric patients with sickle cell disease | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004840-27 | Sponsor Protocol Number: BO42452 | Start Date*: 2021-06-21 | ||||||||||||||||
Sponsor Name:F.Hoffmann-La Roche Ltd | ||||||||||||||||||
Full Title: A PHASE IB RANDOMIZED, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF CROVALIMAB FOR THE MANAGEMENT OF ACUTE UNCOMPLICATED VASO-OCCLUSIVE EPISOD... | ||||||||||||||||||
Medical condition: Sickle cell disease (SCD); vaso-occlusive episodes (VOE) in SCD | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Ongoing) IT (Ongoing) ES (Ongoing) NL (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004839-25 | Sponsor Protocol Number: BO42451 | Start Date*: 2021-08-18 | ||||||||||||||||
Sponsor Name:F. HOFFMANN - LA ROCHE LTD. | ||||||||||||||||||
Full Title: A RANDOMIZED DOUBLE-BLIND PHASE IIA STUDY EVALUATING THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CROVALIMAB AS ADJUNCT TREATMENT IN PREVENTION OF VASO-OCCLUSIVE EPISODES (VOE) I... | ||||||||||||||||||
Medical condition: Sickle Cell Disease (SCD); vaso-occlusive episodes in SCD | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Ongoing) ES (Ongoing) FR (Trial now transitioned) NL (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004995-17 | Sponsor Protocol Number: NL7507301820 | Start Date*: 2021-03-11 |
Sponsor Name:AMsterdam UMC-AMC | ||
Full Title: Low dose iron chelation as TReatment of Oxidative stress in Sickle cell disease; TROS study | ||
Medical condition: Sickle cell disease (an hereditary hemoglobinopathy) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-003585-40 | Sponsor Protocol Number: NL.TACRO.10.7.19 | Start Date*: 2019-12-17 | |||||||||||
Sponsor Name:St. Antonius Hospital | |||||||||||||
Full Title: An uncontrolled, open label pilot-study assessing the efficacy in reducing bleeding severity, and the safety of oral tacrolimus in patients with hereditary hemorrhagic telangiectasia | |||||||||||||
Medical condition: Gastrointestinal bleeding and epistaxis caused by hereditary hemorrhagic telangiectasia. Hereditary Hemorrhagic Telangiectasia (HHT) is an autosomal dominant inherited disease characterized by muco... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001442-19 | Sponsor Protocol Number: IIBSP-COV-2020-23 | Start Date*: 2020-04-02 |
Sponsor Name:INSTITUT DE RECERCA H. SANTA CREU I SANT PAU | ||
Full Title: Pilot, randomized, multicenter, open-label clinical trial of combined use of hydroxychloroquine, azithromycin, and tocilizumab for the treatment of SARS-CoV-2 infection (COVID-19) | ||
Medical condition: COVID19 | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-000350-11 | Sponsor Protocol Number: 2032/MUL | Start Date*: 2014-05-28 | |||||||||||||||||||||
Sponsor Name:Multiplex Pharma Holdings LLC | |||||||||||||||||||||||
Full Title: An open label, randomized study to investigate the safety of weekly pentosan polysulfate injections in adult patients with Mucopolysaccharidosis Type I receiving enzyme replacement therapy. | |||||||||||||||||||||||
Medical condition: Mucopolysaccharidosis type I (alpha-L-Iduronidase deficiency) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-002695-45 | Sponsor Protocol Number: 15-156 | Start Date*: 2018-05-16 |
Sponsor Name:RWTH Aachen University represented by the Rector, himself, represented by the Dean of the Medical Faculty | ||
Full Title: Effect of Empagliflozin on Cardiac Output in Patients with Acute Heart Failure (EMPA Acute Heart Failure) | ||
Medical condition: Patients with acute heart failure | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2019-002240-24 | Sponsor Protocol Number: SIMASPK01b | Start Date*: 2019-06-27 |
Sponsor Name:Institut klinické a experimentální medicíny | ||
Full Title: The evolution of advanced microangiopathic diabetic complications before and after simultaneous pancreas and kidney transplantation evaluated with progressive non-invasive methods | ||
Medical condition: Surgical complications (hernia) after simultaneous pancreas and kidney transplantation | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: CZ (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-003880-24 | Sponsor Protocol Number: ACT16832 | Start Date*: 2021-03-24 | |||||||||||
Sponsor Name:Sanofi-Aventis Recherche & Developpement | |||||||||||||
Full Title: A multicenter, open-label, non-randomized, Phase 1b/2 study to evaluate the safety, pharmacokinetics,and efficacy of subcutaneous isatuximab in adults with warm autoimmune hemolytic anemia | |||||||||||||
Medical condition: Warm autoimmune hemolytic anemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) HU (Completed) NL (Completed) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-000844-17 | Sponsor Protocol Number: PsA 1.1 | Start Date*: 2006-05-29 |
Sponsor Name:Vienna Medical University | ||
Full Title: A multi-centre randomized placebo-controlled double blind study of Rituximab in patients with active PsA | ||
Medical condition: Psoriatic Arthritis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) SK (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-003715-26 | Sponsor Protocol Number: C4221022 | Start Date*: 2022-06-27 | ||||||||||||||||
Sponsor Name:Pfizer Inc. | ||||||||||||||||||
Full Title: A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND CETUXIMAB PLUS PEMBROLIZUMAB VERSUS PEMBROLIZUMAB ALONE IN PARTICIPANTS WITH PREVIOUSLY UNTREATED BRAF V600E-MUTANT, MSI-H/DMMR METASTATIC... | ||||||||||||||||||
Medical condition: MSI-H/dMMR metastatic colorectal cancer. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NO (Ongoing) DE (Ongoing) ES (Ongoing) SE (Ongoing) BE (Ongoing) SK (Ongoing) IT (Ongoing) DK (Ongoing) NL (Ongoing) PL (Ongoing) CZ (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005559-17 | Sponsor Protocol Number: ACA-SPAI-12-07 | Start Date*: 2013-04-22 | |||||||||||
Sponsor Name:Rosa Herrera Castro | |||||||||||||
Full Title: Hemodynamic consequences of isobaric levobupivacaine versus hyperbaric bupivacaine for spinal anesthesia in patients over 65 years, underwent hip surgery | |||||||||||||
Medical condition: In patients 65 years or older undergoing hip surgery. | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003113-26 | Sponsor Protocol Number: CoLeBu | Start Date*: 2018-05-09 | |||||||||||
Sponsor Name:ROSA HERRERA CASTRO | |||||||||||||
Full Title: Hemodynamic safety of isobaric levobupivacaine versus isobaric bupivacaine for spinal anesthesia in patients over 65 years, underwent hip surgery. | |||||||||||||
Medical condition: In patients 65 years or older undergoing hip surgery. | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-006161-13 | Sponsor Protocol Number: ML19983 | Start Date*: 2007-06-22 |
Sponsor Name:Roche Pharma AG | ||
Full Title: A single arm Phase II study to assess efficacy and safety of bevacizumab in combination with the standard therapy (interferon alfa-2a and vinblastine) as first-line treatment for patients with meta... | ||
Medical condition: Metastatic renal cell cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.